First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

被引：1

作者：

Shen, Lin ^{[1
]}

Zhang, Yanqiao ^{[2
]}

Li, Ziyu ^{[3
]}

Zhang, Xiaotian ^{[1
]}

Gao, Xiangyu ^{[1
]}

Liu, Bo ^{[4
]}

Wang, Yusheng ^{[5
]}

Ba, Yi ^{[6
]}

Li, Ning ^{[7
]}

Zhang, Ruixing ^{[8
]}

Zhang, Jingdong ^{[9
]}

Chen, Ye ^{[10
]}

Chen, Jian ^{[11
]}

Huang, Mingzhu ^{[12
]}

Fu, Yang ^{[13
]}

Liu, Mulin ^{[14
]}

Liu, Zheng ^{[15
]}

Zhao, Jun ^{[16
]}

Li, Wei ^{[17
]}

Wei, Jia ^{[18
]}

Li, Changzheng ^{[4
]}

Xu, Nong ^{[19
]}

Guo, Zengqing ^{[20
]}

Cao, Bangwei ^{[21
]}

Liu, Lian ^{[22
]}

Nie, Peng ^{[23
]}

Wan, Lixin ^{[24
]}

Sheng, Lili ^{[25
]}

Liu, Zhenyang ^{[26
]}

He, Yifu ^{[27
]}

Gu, Kangsheng ^{[28
]}

Wu, Guowu ^{[29
]}

Wang, Weibo ^{[30
]}

Zhang, Futong ^{[31
]}

Qiu, Wensheng ^{[32
]}

Guo, Jun ^{[33
]}

Ying, Jieer ^{[34
]}

Pan, Hongming ^{[35
]}

Xu, Huiting ^{[36
]}

Yuan, Yuan ^{[37
]}

Bai, Yuansong ^{[38
]}

Wang, Zhenghua ^{[39
]}

Xu, Jiye ^{[40
]}

Zhao, Xuehong ^{[41
]}

Liu, Hao ^{[42
]}

Zhang, Xizhi ^{[43
]}

Dai, Wenxiang ^{[44
]}

Xu, Hongyan ^{[45
]}

Liu, Ming ^{[46
]}

Xie, Lin ^{[47
]}

机构：

[1] Peking Univ, State Key Lab Holist Integrat Management Gastroint, Beijing Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst, Beijing, Peoples R China

[2] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[3] Peking Univ, Gastrointestinal Canc Ctr, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China

[4] Shandong Canc Hosp, Dept Gastroenterol, Jinan, Peoples R China

[5] Shanxi Prov Canc Hosp, Taiyuan, Peoples R China

[6] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China

[7] Henan Canc Hosp, Zhengzhou, Peoples R China

[8] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China

[9] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

[10] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China

[11] Yantai Yuhuangding Hosp, Yantai, Peoples R China

[12] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[13] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[14] Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China

[15] HanDan Cent Hosp, Handan, Peoples R China

[16] Changzhi Peoples Hosp, Changzhi, Peoples R China

[17] Jilin Univ, Bethune Hosp 1, Changchun, Peoples R China

[18] Nanjing Drum Tower Hosp, Nanjing, Peoples R China

[19] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China

[20] Fujian Canc Hosp, Fuzhou, Peoples R China

[21] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[22] Shandong Univ, Qilu Hosp, Jinan, Peoples R China

[23] Gansu Wuwei Tumour Hosp, Wuwei, Peoples R China

[24] Nanyang Cent Hosp, Nanyang, Peoples R China

[25] Wannan Med Coll, Affiliated Hosp 1, Wuhu, Peoples R China

[26] Hunan Canc Hosp, Changsha, Peoples R China

[27] Anhui Prov Canc Hosp, Hefei, Peoples R China

[28] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China

[29] Meizhou Peoples Hosp, Meizhou, Peoples R China

[30] Shandong Prov Hosp, Jinan, Peoples R China

[31] Shijiazhuang Peoples Hosp, Shijiazhuang, Peoples R China

[32] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China

[33] Xingtai Peoples Hosp, Xingtai, Peoples R China

[34] Zhejiang Canc Hosp, Hangzhou, Peoples R China

[35] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China

[36] Hubei Canc Hosp, Wuhan, Peoples R China

[37] Xuzhou Cent Hosp, Xuzhou, Peoples R China

[38] Jilin Univ, Bethune Hosp 3, Changchun, Peoples R China

[39] Jinzhou Med Univ, Affiliated Hosp 1, Jinzhou, Peoples R China

[40] Zhoukou Cent Hosp, Zhoukou, Peoples R China

[41] Linfen Cent Hosp, Linfen, Peoples R China

[42] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China

[43] Northern Jiangsu Peoples Hosp, Yangzhou, Peoples R China

[44] Univ South China, Affiliated Hosp 1, Hengyang, Peoples R China

[45] Weihai Municipal Hosp, Weihai, Peoples R China

[46] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[47] Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China

[48] Xinjiang Med Univ, Affiliated Canc Hosp, Urumqi, Peoples R China

[49] Taizhou Hosp Zhejiang Prov, Linhai, Peoples R China

[50] China Med Univ, Hosp 1, Shenyang, Peoples R China

来源：

NATURE MEDICINE | 2025年

基金：

中国国家自然科学基金;

关键词：

OPEN-LABEL; CANCER; IPILIMUMAB; MULTICENTER; NIVOLUMAB; COMBINATION; CARBOPLATIN; PACLITAXEL; HER2;

D O I：

10.1038/s41591-024-03450-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Programmed cell death protein-1 (PD-1) inhibitors plus chemotherapy have been the standard of care in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma; however, the survival benefits are modest in patients with low programmed death ligand 1 (PD-L1) expression. Here we investigated the efficacy and safety of cadonilimab (PD-1/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody) plus chemotherapy as first-line treatment in G/GEJ adenocarcinoma. The prespecified interim analysis is reported here. This was a randomized, double-blind, placebo-controlled phase 3 study. Eligible patients were adults with untreated, unresectable, locally advanced or metastatic G/GEJ adenocarcinoma. Patients were randomized 1:1 to receive cadonilimab (10 mg kg(-1) every 3 weeks) or placebo plus chemotherapy (every 3 weeks). The primary endpoint was overall survival (OS) in the intention-to-treat population (one-sided significance level, P = 0.025). Secondary endpoints included OS in patients with a PD-L1 combined positive score >= 5, progression-free survival, objective response rate, duration of response and safety. As of 18 August 2023, 610 patients from 75 study centers were randomized to cadonilimab (n = 305) or placebo (n = 305). With a median follow-up of 18.7 months, the cadonilimab group had a significantly longer median OS (14.1 versus 11.1 months; hazard ratio (HR) 0.66; 95% confidence interval (CI) 0.54-0.81; P < 0.001) than the placebo group. The primary endpoint was met. The median progression-free survival was 7.0 months versus 5.3 months (HR 0.53, 95% CI 0.44-0.65). The median OS in patients with a PD-L1 combined positive score >= 5 was 15.3 months versus 10.9 months (HR 0.58, 95% CI 0.41-0.82). The objective response rate was 65.2% versus 48.9% with a median duration of response of 8.8 months versus 4.4 months. Grade >= 3 treatment-related adverse events occurred in 65.9% of the cadonilimab group and 53.6% of the placebo group, and the most common were decreased platelet count, decreased neutrophil count and anemia. Most of the immune-related adverse events were grade 1 or 2. No new safety signals were observed. Cadonilimab plus chemotherapy significantly improved OS with a manageable safety profile in patients with advanced G/GEJ adenocarcinoma.

引用

页码：1163 / 1170

页数：23

共 50 条

[21] Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
Maria Di Bartolomeo
Monica Niger
Federica Morano
Salvatore Corallo
Maria Antista
Stefano Tamberi
Sara Lonardi
Samantha Di Donato
Rossana Berardi
Mario Scartozzi
Giovanni Gerardo Cardellino
Francesco Di Costanzo
Lorenza Rimassa
Alberto Gianluigi Luporini
Raffaella Longarini
Alberto Zaniboni
Alessandro Bertolini
Gianluca Tomasello
Graziella Pinotti
Giorgio Scagliotti
Giampaolo Tortora
Andrea Bonetti
Andrea Spallanzani
Giovanni Luca Frassineti
Davide Tassinari
Francesco Giuliani
Saverio Cinieri
Evaristo Maiello
Claudio Verusio
Sergio Bracarda
Vincenzo Catalano
Michele Basso
Libero Ciuffreda
Ferdinando De Vita
Hector Soto Parra
Lorenzo Fornaro
Marta Caporale
Filippo de Braud
Filippo Pietrantonio
BMC Cancer, 19
[22] Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
Di Bartolomeo, Maria
Niger, Monica
Morano, Federica
Corallo, Salvatore
Antista, Maria
Tamberi, Stefano
Lonardi, Sara
Di Donato, Samantha
Berardi, Rossana
Scartozzi, Mario
Cardellino, Giovanni Gerardo
Di Costanzo, Francesco
Rimassa, Lorenza
Luporini, Alberto Gianluigi
Longarini, Raffaella
Zaniboni, Alberto
Bertolini, Alessandro
Tomasello, Gianluca
Pinotti, Graziella
Scagliotti, Giorgio
Tortora, Giampaolo
Bonetti, Andrea
Spallanzani, Andrea
Frassineti, Giovanni Luca
Tassinari, Davide
Giuliani, Francesco
Cinieri, Saverio
Maiello, Evaristo
Verusio, Claudio
Bracarda, Sergio
Catalano, Vincenzo
Basso, Michele
Ciuffreda, Libero
De Vita, Ferdinando
Parra, Hector Soto
Fornaro, Lorenzo
Caporale, Marta
de Braud, Filippo
Pietrantonio, Filippo
BMC CANCER, 2019, 19 (1)
[23] Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
Yoon, H. H.
Bendell, J. C.
Braiteh, F. S.
Firdaus, I.
Philip, P. A.
Cohn, A. L.
Lewis, N.
Anderson, D. M.
Arrowsmith, E.
Schwartz, J. D.
Gao, L.
Hsu, Y.
Xu, Y.
Ferry, D.
Alberts, S. R.
Wainberg, Z. A.
ANNALS OF ONCOLOGY, 2016, 27 (12) : 2196 - 2203
[24] Alliance A022102: Randomized phase III trial of mFOLFIRINOX plus /- nivolumab vs. FOLFOX plus /- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA)
Park, Haeseong
Geyer, Susan Michelle
Klute, Kelsey
Bleeker, Jonathan
King, Daniel
Strickland, Matthew
Goodrich, Austin
Carlisle, Destin
Shergill, Ardaman
O'Reilly, Eileen Mary
Meyerhardt, Jeffrey A.
Shah, Manish A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.
Tabernero, Josep
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles S.
Janjigian, Yelena Y.
Bhagia, Pooja
Li Kan
Adelberg, David E.
Kui, Qin Shu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[26] An exploratory phase II trial of low-dose decitabine and sintilimab combined with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Du, Yunyi
Zhang, Xiaoling
Ma, Ning
Yang, Wei
Yang, Bo
Su, Fei
Zong, Liang
Hu, Wenqing
Zhao, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 390 - 390
[27] HLX22 plus HLX02 and XELOX as first-line therapy for HER2positive advanced gastric/gastroesophageal junction cancer: Updated results from a randomized, double-blind phase II study
Li, J.
Gao, Y.
Li, N.
Qiu, M.
Zhang, Y.
Yang, M.
Lu, L.
Li, W.
Ma, Y.
Hou, X.
Sun, G.
Cai, M.
Wang, J.
Lu, J.
Zhong, D.
Yang, F.
Yu, H.
Li, J.
Wang, Q.
Zhu, J.
ANNALS OF ONCOLOGY, 2024, 35 : S171 - S172
[28] HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.
Li, Jin
Gao, Yong
Li, Ning
Qiu, Meng
Zhang, Yan-Qiao
Yang, Mudan
Lu, Linzhi
Li, Wei
Ma, Yuntao
Hou, Xiaoming
Sun, Guoping
Cai, Mingquan
Wang, Jingran
Lu, Jianwei
Zhong, Diansheng
Yang, Futang
Li, Jing
Wang, Qingyu
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 354 - 354
[29] Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
Cheng, Y.
Yang, R.
Chen, J.
Zhang, W.
Xie, C.
Hu, Q.
Zhou, N.
Huang, C.
Wei, S.
Sun, H.
Li, X.
Yu, Y.
Lai, J.
Yang, H.
Fang, H.
Chen, H.
Zhang, P.
Gu, K.
Wang, Q.
Shi, J.
Yi, T.
Xu, X.
Ye, X.
Wang, D.
Xie, C.
Liu, C.
Zheng, Y.
Lin, D.
Zhuang, W.
Lu, P.
Yu, G.
Li, J.
Gu, Y.
Li, B.
Wu, R.
Jiang, O.
Wang, Z.
Wu, G.
Lin, H.
Zhong, D.
Xu, Y.
Shu, Y.
Wu, D.
Chen, X.
Wang, J.
Wang, M.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S44 - S44
[30] Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial
Nanni, O.
Amadori, D.
De Censi, A.
Rocca, A.
Freschi, A.
Bologna, A.
Gianni, L.
Rosetti, F.
Amaducci, L.
Cavanna, L.
Foca, F.
Sarti, S.
Serra, P.
Valmorri, L.
Bruzzi, P.
Corradengo, D.
Gennari, A.
Scaltriti, Laura
Turolla, Gianni Michele
Dazzi, Claudio
Cortesi, Laura
Giovanis, Petros
Saracchini, Silvana
Ciccarese, Mariangela
Carrozza, Francesco
BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (02) : 433 - 442

← 1 2 3 4 5 →